CRISPR Mouse for Cardiovascular Disease Modeling    

Cardiovascular disease remains a major cause of morbidity and mortality in developed countries. In recent decades, efforts have been made to characterize the molecular and pathophysiological features of the diseased heart and vascular system. Mouse models have been particularly powerful in elucidating the complex signaling pathways, genetic and epigenetic regulatory circuits, and multicellular interactions underlying cardiovascular disease.

The advent of CRISPR genome editing has ushered in a new era of cardiovascular research and the possibility of genetic correction of disease. Next-generation sequencing technologies have greatly accelerated the identification of disease-causing mutations, and advances in gene editing technologies have enabled rapid mimicry of these mutations in mouse- and patient-derived induced pluripotent stem cells. The ability to correct genetic drivers of cardiovascular disease by delivering gene-edited components in vivo represents an exciting therapeutic frontier.

Fig. 1 Generation of Myh6-Cas9 transgenic mice. (Carroll KJ, et al., 2016)

Solution

CRISPR/Cas9 Platform^CB is dedicated to providing professional CRISPR/Cas9-based cardiovascular disease modeling services and solutions to our clients. We can perform genome editing on animal models, both at the single-cell embryonic stage and at the postnatal stage. With CRISPR/Cas9-based technology, we generate mutant mice in a single step, including co-injection of Cas9 mRNA, different sgRNAs and DNA donors into fertilized eggs. Our improved design of guide RNAs, as well as continuous optimization of experimental conditions, ensures the establishment of very consistent protocols that are fully reliable for generating knockouts and knockout point mutations useful for cardiac disease modeling, cardiac gene editing, and exploring potential gene therapies.

With experienced scientists and an excellent gene editing platform, our staff has successfully produced a variety of gene KO mice and knock-in mice for cardiovascular disease research using CRISPR/Cas9, including but not limited to

• Atherosclerosis gene editing mouse model
• Heart failure gene editing mouse model
• Cardiomyopathy gene editing mouse model
• Arrhythmia gene editing mouse model
• PRKAG2 heart syndrome gene editing mouse model
• Marfan's syndrome (MFS) gene editing mouse model

What Can We Help You?

• Rapidly and efficiently analyze the function of any coding gene in the heart
• Characterize cardiac phenotypes in embryos as well as mimic adult heart disease
• Explore the specific role of genes whose expression is not restricted to the heart in cardiac function and/or development
• High throughput genetic screening
• Explore gene therapy for cardiac disease

Related Services

• Conditional Knockout Mouse
• Conventional Knockout Mouse
• Point Mutation Mouse
• CRISPR/Cas9 Knockin Mouse
• Rosa26 Knockin Mouse

Related Products

• CRISPR/Cas9 Kits
• Cas9 Protein
• Cas9 mRNA
• Cas9 Related Plasmids
• Pre-made Cas9 Virus Particles

CRISPR/Cas9 Platform^CB is the world's leading gene editing biotechnology company, and we are committed to providing our clients with the most professional and comprehensive gene editing technology solutions. To support your project, we provide comprehensive custom CRISPR/Cas9 gene editing services from strategy design to final cardiovascular disease model generation.